US6790965B1
(en)
|
1994-05-06 |
2004-09-14 |
Pharmacopeia Drug Discovery, Inc. |
Combinatorial dihydrobenzopyran library
|
DE19610103A1
(en)
|
1996-03-15 |
1997-09-18 |
Basf Ag |
Cycloalkyl derivatives and their synthesis on solid phase
|
DE19621177A1
(en)
|
1996-05-24 |
1997-11-27 |
Basf Ag |
Carbohydrate derivatives and their synthesis on solid phase
|
DE19626762A1
(en)
|
1996-07-03 |
1998-01-08 |
Basf Ag |
Enzymatically cleavable linker for solid phase synthesis
|
AU3632297A
(en)
|
1996-08-26 |
1998-03-19 |
Pfizer Inc. |
Spirocyclic dopamine receptor subtype ligands
|
US5908960A
(en)
*
|
1997-05-07 |
1999-06-01 |
Smithkline Beecham Corporation |
Compounds
|
US6004823A
(en)
*
|
1997-05-07 |
1999-12-21 |
Smithkline Beecham Corporation |
Compounds
|
EP0905512A1
(en)
*
|
1997-09-25 |
1999-03-31 |
Cerep |
Method of identification of leads or active compounds
|
US6362009B1
(en)
|
1997-11-21 |
2002-03-26 |
Merck & Co., Inc. |
Solid phase synthesis of heterocycles
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US5976813A
(en)
*
|
1997-12-12 |
1999-11-02 |
Abbott Laboratories |
Continuous format high throughput screening
|
DK1721979T3
(en)
|
1998-11-27 |
2010-12-13 |
Ucb Pharma Sa |
Compositions and Methods for Increasing Bone Mineralization
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US6906067B2
(en)
|
1999-12-28 |
2005-06-14 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of TNF-α expression
|
AU2001250774B2
(en)
|
2000-02-08 |
2005-01-27 |
Sangamo Biosciences, Inc. |
Cells expressing zinc finger proteins for drug discovery
|
US7923542B2
(en)
|
2000-04-28 |
2011-04-12 |
Sangamo Biosciences, Inc. |
Libraries of regulatory sequences, methods of making and using same
|
US7217509B2
(en)
|
2000-04-28 |
2007-05-15 |
Sangamo Biosciences, Inc. |
Databases of regulatory sequences; methods of making and using same
|
WO2001084148A2
(en)
|
2000-04-28 |
2001-11-08 |
Sangamo Biosciences, Inc. |
Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
|
WO2001083819A2
(en)
|
2000-04-28 |
2001-11-08 |
Sangamo Biosciences, Inc. |
Methods for designing exogenous regulatory molecules
|
AU2001255748B2
(en)
|
2000-04-28 |
2006-08-10 |
Sangamo Therapeutics, Inc. |
Methods for binding an exogenous molecule to cellular chromatin
|
WO2001084149A2
(en)
|
2000-04-29 |
2001-11-08 |
University Of Iowa Research Foundation |
Diagnostics and therapeutics for macular degeneration-related disorders
|
WO2002020509A2
(en)
*
|
2000-09-06 |
2002-03-14 |
Bayer Aktiengesellschaft |
Medicaments against viral infections
|
EP1343973B2
(en)
|
2000-11-16 |
2020-09-16 |
California Institute Of Technology |
Apparatus and methods for conducting assays and high throughput screening
|
WO2002090600A2
(en)
|
2001-05-08 |
2002-11-14 |
Darwin Molecular Corporation |
A method for regulating immune function in primates using the foxp3 protein
|
WO2002100172A1
(en)
|
2001-06-11 |
2002-12-19 |
Xenoport, Inc. |
Administration of agents via the pept-2 transporter
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
EP2258724A1
(en)
|
2002-11-21 |
2010-12-08 |
Celltech R & D, Inc. |
Modulating immune responses using multimerized anti-CD83 antibodies
|
KR20090046973A
(en)
|
2002-11-27 |
2009-05-11 |
아이알엠 엘엘씨 |
Methods and compositions for inducing apoptosis in cancer cells
|
AU2004209981B2
(en)
|
2003-02-01 |
2009-02-26 |
Janssen Sciences Ireland Uc |
Active immunization to generate antibodies to soluble A-beta
|
JPWO2004092179A1
(en)
*
|
2003-04-14 |
2006-07-06 |
日本曹達株式会社 |
Spiro derivatives, production methods and antioxidants
|
ES2640669T3
(en)
|
2003-05-19 |
2017-11-03 |
Prothena Biosciences Limited |
Truncated alpha-synuclein fragments in lewy body disease
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
US20060162014A1
(en)
|
2003-07-07 |
2006-07-20 |
Jaffe Eileen K |
Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
|
US8153410B2
(en)
|
2003-07-07 |
2012-04-10 |
Fox Chase Cancer Center |
Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
|
NZ546834A
(en)
*
|
2003-10-01 |
2010-03-26 |
Adolor Corp |
Spirocyclic heterocyclic derivatives and methods of their use
|
WO2005043118A2
(en)
|
2003-10-27 |
2005-05-12 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
TWI379839B
(en)
|
2003-12-17 |
2012-12-21 |
Wyeth Llc |
Aβ immunogenic peptide carrier conjugates and methods of producing same
|
WO2005058940A2
(en)
|
2003-12-17 |
2005-06-30 |
Wyeth |
Immunogenic peptide carrier conjugates and methods of producing same
|
WO2006135382A2
(en)
|
2004-08-04 |
2006-12-21 |
Chemocentryx, Inc. |
Enzymatic activities in chemokine-mediated inflammation
|
EA013752B1
(en)
|
2004-08-09 |
2010-06-30 |
Элан Фармасьютикалз, Инк. |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
CA2597411C
(en)
|
2005-02-14 |
2014-08-12 |
University Of Iowa Research Foundation |
Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration
|
RU2422446C2
(en)
|
2005-07-19 |
2011-06-27 |
Мерк Шарп Энд Домэ Корп. |
Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
|
WO2007030560A2
(en)
|
2005-09-08 |
2007-03-15 |
Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine |
Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
|
CN101309923A
(en)
*
|
2005-11-14 |
2008-11-19 |
索尔瓦药物有限公司 |
N-sulfamoyl-N -benzopyranpiperidines as inhibitors of carbonic anhydrases
|
AR057570A1
(en)
|
2005-11-14 |
2007-12-05 |
Solvay Pharm Gmbh |
DERIVATIVES OF N-SULFAMOIL-N'-BENZOPIRANOPIPERIDINAS ESPIROCONDENSADAS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, A PROCEDURE FOR THEIR PREPARATION AND ITS USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY ISOIDAS IIB
|
EP1996718B1
(en)
|
2006-03-06 |
2011-11-30 |
Ceetox Inc. |
Toxicity screening methods
|
CA2653628C
(en)
|
2006-06-01 |
2015-07-14 |
Elan Pharmaceuticals, Inc. |
Neuroactive fragments of app
|
AU2008205642B2
(en)
|
2007-01-12 |
2013-06-06 |
Msd K.K. |
Spirochromanon derivatives
|
PE20081559A1
(en)
|
2007-01-12 |
2008-11-20 |
Merck & Co Inc |
SPIROCHROMANONE DERIVATIVES SUBSTITUTED AS ACETYL COA CARBOXYLASE INHIBITORS
|
LT3067066T
(en)
|
2007-02-23 |
2019-06-25 |
Prothena Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
DK3067066T3
(en)
|
2007-02-23 |
2019-05-20 |
Prothena Biosciences Ltd |
PREVENTION AND TREATMENT OF SYNUCLEINOPATIC AND AMYLOIDOGENIC DISEASE
|
EP2231181B1
(en)
|
2007-12-17 |
2016-02-17 |
Marfl AB |
New vaccine for the treatment of mycobacterium related disorders
|
EA036059B1
(en)
|
2007-12-28 |
2020-09-21 |
Протена Байосайенсиз Лимитед |
Method of producing and antibody or fragment thereof that specifically binds to an aggregated amyloid protein
|
WO2009088876A2
(en)
|
2007-12-31 |
2009-07-16 |
Baxter International Inc. |
Transgenic non-human animals expressing human blood clotting factors and uses thereof
|
EP2240604B1
(en)
|
2008-01-18 |
2012-07-25 |
North Carolina State University |
Peptides and methods of use as therapeutics and screening agents
|
CA2729412A1
(en)
|
2008-07-04 |
2010-01-07 |
Banyu Pharmaceutical Co., Ltd. |
Novel spirochromanone carboxylic acids
|
JP5628807B2
(en)
|
2008-08-18 |
2014-11-19 |
ソウル ナショナル ユニバーシティー インダストリー ファウンデーション |
Method for regulating cancer metastasis or cancer cell migration by regulating intracellular levels of lysyl tRNA synthetase
|
AR075854A1
(en)
*
|
2009-03-13 |
2011-05-04 |
Vitae Pharmaceuticals Inc |
BETA-SECRETASA INHIBITORS
|
EP2443459B1
(en)
|
2009-06-19 |
2018-12-26 |
The Arizona Board of Regents, A Body Corporate Of the State of Arizona acting for and on behalf Of Arizona State University |
Compound arrays for sample profiling
|
EP2539322B1
(en)
|
2010-02-24 |
2014-01-01 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of beta-secretase
|
WO2011140425A1
(en)
|
2010-05-06 |
2011-11-10 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
|
AU2012212196B2
(en)
|
2011-02-02 |
2016-10-13 |
Vertex Pharmaceuticals Incorporated |
Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
|
US10385070B2
(en)
|
2011-02-18 |
2019-08-20 |
Vertex Pharmaceuticals Incorporated |
Chroman-spirocyclic piperidine amides as modulators of ion channels
|
CA2829803A1
(en)
|
2011-03-14 |
2012-09-20 |
Vertex Pharmaceuticals Incorporated |
Morpholine-spirocyclic piperidine amides as modulators of ion channels
|
US8975293B2
(en)
|
2011-05-26 |
2015-03-10 |
Regents Of The University Of Michigan |
Epigenetic co-repressors of the gamma-globin gene and methods of using same
|
KR101425032B1
(en)
|
2011-09-22 |
2014-07-31 |
재단법인 의약바이오컨버젼스연구단 |
Novel use of leucyl tRNA synthetase
|
WO2013044029A1
(en)
|
2011-09-23 |
2013-03-28 |
University Of Louisville Research Foundation, Inc. |
Methods and compositions for expanding cells and improving engraftment
|
KR101398079B1
(en)
|
2011-10-10 |
2014-05-27 |
재단법인 의약바이오컨버젼스연구단 |
method for screening an agent preventing or treating cancer using glycyl-tRNA synthetase and cadherin
|
WO2013078138A1
(en)
|
2011-11-21 |
2013-05-30 |
OSI Pharmaceuticals, LLC |
Proton nmr spectroscopy for biochemical screening
|
TWI557112B
(en)
|
2012-03-05 |
2016-11-11 |
百靈佳殷格翰國際股份有限公司 |
Inhibitors of beta-secretase
|
TW201422592A
(en)
|
2012-08-27 |
2014-06-16 |
Boehringer Ingelheim Int |
Inhibitors of beta-secretase
|
US9290477B2
(en)
|
2012-09-28 |
2016-03-22 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of β-secretase
|
WO2014145123A2
(en)
|
2013-03-15 |
2014-09-18 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State Unversity |
Peptide array quality control
|
WO2014144383A1
(en)
|
2013-03-15 |
2014-09-18 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Non-covalent patterned chemical features and use thereof in maldi-based quality control
|
WO2016040895A1
(en)
|
2014-09-12 |
2016-03-17 |
xxTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
Wnt signaling agonist molecules
|
US10196613B2
(en)
|
2014-12-19 |
2019-02-05 |
Regeneron Pharmaceuticals, Inc. |
Stem cells for modeling type 2 diabetes
|
US10758886B2
(en)
|
2015-09-14 |
2020-09-01 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Conditioned surfaces for in situ molecular array synthesis
|
WO2017208210A1
(en)
|
2016-06-03 |
2017-12-07 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
AU2017281040A1
(en)
|
2016-06-20 |
2019-01-24 |
Healthtell Inc. |
Methods for diagnosis and treatment of autoimmune diseases
|
WO2017223116A2
(en)
|
2016-06-20 |
2017-12-28 |
Healthtell Inc. |
Methods for differential diagnosis of autoimmune diseases
|
HUE055402T2
(en)
|
2016-07-06 |
2021-11-29 |
Prothena Biosciences Ltd |
Assay for detecting total and s129 phosphorylated alpha-synuclein
|
BR112019001783A2
(en)
|
2016-07-29 |
2019-05-07 |
Regeneron Pharmaceuticals, Inc. |
nonhuman mammal, and methods for producing the nonhuman mammal and screening a compound.
|
MA46523A
(en)
|
2016-10-12 |
2019-08-21 |
Janssen Biotech Inc |
PROCESSES FOR SCREENING MODULATORS OF A GDF15 TYPE BIOLOGICAL ACTIVITY
|
CN110168370A
(en)
|
2016-11-11 |
2019-08-23 |
健康之语公司 |
Method for identifying candidate biomarker
|
EP3619534A1
(en)
|
2017-05-05 |
2020-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Microtubule-targeting drugs as immune checkpoint inhibitors and methods of screening novel immune checkpoint inhibitors for the treatment of cancers and infectious diseases
|
WO2019055618A1
(en)
|
2017-09-15 |
2019-03-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
WO2019094735A1
(en)
|
2017-11-10 |
2019-05-16 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising slc30a8 mutation and methods of use
|
EP3823979A1
(en)
|
2018-07-20 |
2021-05-26 |
AiCuris GmbH & Co. KG |
Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
|
CN113966401A
(en)
|
2019-04-10 |
2022-01-21 |
犹他大学研究基金会 |
HTRA1 modulation for the treatment of AMD
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
WO2022235929A1
(en)
|
2021-05-05 |
2022-11-10 |
Radius Pharmaceuticals, Inc. |
Animal model having homologous recombination of mouse pth1 receptor
|